These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25338958)

  • 41. The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.
    Yu C; Gong X; Yang Q; Lian J; Xu K; Ruan B; Li L
    Liver Int; 2015 May; 35(5):1549-56. PubMed ID: 25312687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients].
    Zheng Q; Zhu YY; Chen J; Liu YR; You J; Zeng DW; Lin S; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Nov; 20(11):801-6. PubMed ID: 23206296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
    Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY
    Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A possible role for NKT-like cells in patients with chronic hepatitis B during telbivudine treatment.
    Diao H; He J; Zheng Q; Chen J; Cui G; Wei Y; Ye P; Kohanawa M; Li L
    Immunol Lett; 2014 Jul; 160(1):65-71. PubMed ID: 24718278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
    Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan.
    Hsu HY; Tsai HY; Wu TC; Chiang CL; Ni YH; Chen PJ; Chang MH
    Liver Int; 2008 Nov; 28(9):1288-97. PubMed ID: 18397229
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
    Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
    Penna A; Laccabue D; Libri I; Giuberti T; Schivazappa S; Alfieri A; Mori C; Canetti D; Lampertico P; Viganò M; Colombo M; Loggi E; Missale G; Ferrari C
    J Hepatol; 2012 Jun; 56(6):1239-46. PubMed ID: 22326467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduction of HBV replication prolongs the early immunological response to IFNα therapy.
    Tan AT; Hoang LT; Chin D; Rasmussen E; Lopatin U; Hart S; Bitter H; Chu T; Gruenbaum L; Ravindran P; Zhong H; Gane E; Lim SG; Chow WC; Chen PJ; Petric R; Bertoletti A; Hibberd ML
    J Hepatol; 2014 Jan; 60(1):54-61. PubMed ID: 23994382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation between low tapasin expression and impaired CD8+ T‑cell function in patients with chronic hepatitis B.
    Tang Y; Wang J; Zhang Y; Zhuo M; Song L; Tang Z; Zang G; Chen X; Yu Y
    Mol Med Rep; 2016 Oct; 14(4):3315-22. PubMed ID: 27510296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tim-3 expression on peripheral monocytes and CD3+CD16/CD56+natural killer-like T cells in patients with chronic hepatitis B.
    Rong YH; Wan ZH; Song H; Li YL; Zhu B; Zang H; Zhao Y; Liu HL; Zhang AM; Xiao L; Xin SJ; You SL
    Tissue Antigens; 2014 Feb; 83(2):76-81. PubMed ID: 24397461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Influences of the genotypes of HBV and HBeAg regarding their response to PEG-IFN in chronic hepatitis B patients].
    Fan HB; Guo YB; Luo KX; Hou JL; Wang ZH; Zhang MX
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):488-90. PubMed ID: 16042879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune Cell Subsets Evaluation as a Predictive Tool for Hepatitis B Infection Outcome and Treatment Responsiveness.
    Kandilarova SM; Georgieva AI; Mihaylova AP; Baleva MP; Atanasova VK; Petrova DV; Popov GT; Naumova EJ
    Folia Med (Plovdiv); 2017 Mar; 59(1):53-62. PubMed ID: 28384114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
    J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
    Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.